We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

106 hedge funds and large institutions have $344M invested in ChemoCentryx, Inc. in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less capital invested

Capital invested by funds: $354M → $344M (-$10.1M)

5% less call options, than puts

Call options by funds: $1.92M | Put options by funds: $2.02M

8% less funds holding

Funds holding: 115106 (-9)

50% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 18

Holders
106
Holders Change
-9
Holders Change %
-7.83%
% of All Funds
2.42%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
35
Reduced
33
Closed
18
Calls
$1.92M
Puts
$2.02M
Net Calls
-$102K
Net Calls Change
+$10K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$85.6M -$3.14M -260,586 -4%
BlackRock
2
BlackRock
New York
$35.4M +$973K +80,783 +3%
WA
3
Wasatch Advisors
Utah
$30.2M +$132K +10,991 +0.5%
Franklin Resources
4
Franklin Resources
California
$18.3M -$839K -69,600 -5%
Vanguard Group
5
Vanguard Group
Pennsylvania
$16.8M +$1.1M +90,899 +7%
CG
6
Carmignac Gestion
France
$16.4M +$3.32M +275,273 +27%
FCM
7
Farallon Capital Management
California
$14.5M
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$11.3M +$1.84M +153,082 +21%
Renaissance Technologies
9
Renaissance Technologies
New York
$9.76M +$636K +52,800 +7%
NCM
10
Nantahala Capital Management
Connecticut
$8.13M +$339K +28,165 +5%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$6.92M +$2.73M +226,485 +70%
State Street
12
State Street
Massachusetts
$6.25M +$608K +50,434 +11%
BBA
13
Baker Bros. Advisors
New York
$5.23M
TCIM
14
TIAA CREF Investment Management
New York
$4.19M -$415K -34,407 -9%
PAM
15
Panagora Asset Management
Massachusetts
$4.1M -$45.2K -3,752 -1%
Northern Trust
16
Northern Trust
Illinois
$3.79M +$438K +36,343 +14%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$3.29M -$200K -16,617 -6%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.17M +$220K +18,271 +8%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$2.88M -$319K -26,500 -10%
Goldman Sachs
20
Goldman Sachs
New York
$2.76M -$25K -2,074 -0.9%
Arrowstreet Capital
21
Arrowstreet Capital
Massachusetts
$2.66M +$1.39M +115,268 +121%
Millennium Management
22
Millennium Management
New York
$2.5M -$2.29M -190,025 -49%
American Century Companies
23
American Century Companies
Missouri
$2.14M +$62.2K +5,166 +3%
GCP
24
GSA Capital Partners
United Kingdom
$2.08M +$1.23M +102,100 +163%
Two Sigma Investments
25
Two Sigma Investments
New York
$1.78M -$1.41M -116,992 -45%

CCXI Hedge Fund Activity: Q3 2018 in Review

106 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q3 2018, worth a combined $344M — down 2.8% from $354M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CCXI and 9 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 35 added.

The largest buyer was Carmignac Gestion, adding an estimated $3.32M. The largest seller was BVF Inc, cutting an estimated $3.14M.

  • 106 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q3 2018, down from 115 in Q2 2018.
  • Funds reported $344M of ChemoCentryx, Inc. stock for Q3 2018, down 2.8% quarter-over-quarter.
  • 9 funds opened new ChemoCentryx, Inc. positions in Q3 2018 and 18 closed out, a net change of -9 holders.
  • The largest ChemoCentryx, Inc. buyer in Q3 2018 was Carmignac Gestion, an estimated $3.32M added.
  • The largest ChemoCentryx, Inc. seller in Q3 2018 was BVF Inc, an estimated $3.14M sold.

Based on aggregated 13F filings for Q3 2018.